3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
50
Neoplasms
22
Pancreatic Neoplasms
21
Neoplasm Metastasis
12
Lung Neoplasms
12
Brain Neoplasms
9
Squamous Cell Carcinoma of Head and Neck
8
Head and Neck Neoplasms
7
Breast Neoplasms
7
Gliosarcoma
6
Glioblastoma
6
Salivary Gland Neoplasms
5
Rectal Neoplasms
5
Glioma
5
Colorectal Neoplasms
5
Colonic Neoplasms
5
Astrocytoma
5
Unspecified Adult Solid Tumor, Protocol Specific
4
Solid Tumors
4
Esophageal Neoplasms
4
Tongue Neoplasms
3
Prostatic Neoplasms
3
Oligodendroglioma
3
Lymphoma
3
Gallbladder Neoplasms
3
Central Nervous System Neoplasms
3
Carcinoma, Hepatocellular
3
Bile Duct Neoplasms
3
Advanced Cancers
3
Advanced Cancer
3
Interventions
Doxorubicin
4
Radiotherapy
3
belinostat
2
Trabectedin
2
Gemcitabine
2
selinexor
1
sargramostim
1
peposertib
1
pembrolizumab
1
olaratumab
1
liposomal doxorubicin
1
itacitinib
1
futibatinib
1
cixutumumab
1
baricitinib
1
avelumab
1
Specimen Handling
1
Radiation
1
PTC596
1
Nivolumab
1
Magnetic Resonance Spectroscopy
1
Ifosfamide
1
INCB039110
1
Fluorouracil
1
Erlotinib Hydrochloride
1
Dacarbazine
1
Chemotherapy, Adjuvant
1
Celecoxib
1
Biopsy
1
BO-112
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Leiomyosarcoma
×
Erlotinib Hydrochloride
×
Clear all
NCT05827614
2026-01-23
POTENTIATE
Boundless Bio, Inc.
Phase 1
Active not recruiting
85 enrolled